English | Español

Eli Lilly And Company
+ Technology/Innovation
Patient Daily | May 25, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals
+ Technology/Innovation
Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
+ Technology/Innovation
Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
+ Community
Patient Daily | May 9, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
+ Regulatory
Patient Daily | May 9, 2023

Lilly Declares Second-Quarter 2023 Dividend
+ Technology/Innovation
Patient Daily | May 9, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
+ Technology/Innovation
Patient Daily | Apr 26, 2023

Lilly to Divest BAQSIMI to Amphastar
+ Community
Patient Daily | Apr 26, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes